🔥 Friday 23 October 2026 Fri, 23 Oct 2026

Paradigm’s administrators have asked the Supreme Court of Western Australia for up to three more months to assess sale and recapitalisation proposals. Without the extension, they say they would have no alternative but to recommend winding up the biotech.

Acusensus has secured a five-year ACT Government traffic enforcement contract valued at approximately $63 million, with extension options that could lift the total to $210 million. The deal broadens its role from specialist detection to a territory-wide enforcement platform, although rollout is not expected until mid-2027.

Fenix Resources has monetised most of its iron ore swap book for more than A$10 million, converting protection on 480,000 tonnes into near-term cash. The move leaves the company retaining diesel and currency hedges while restoring exposure to prevailing iron ore prices on the settled tonnes.

Arovella has released two clinical batches of its off-the-shelf CAR-iNKT therapy, activated two trial sites and begun screening patients ahead of expected first dosing in October. The biotech ended September with A$11.6 million in cash, rising to about A$15.63 million pro forma after an R&D rebate.

Alkane Resources delivered 40,740 gold equivalent ounces in the September quarter, generated A$102 million in mine operating cash flow and reaffirmed FY27 production guidance. The result also funded the company’s maiden dividend while leaving A$440 million in cash and bullion.

BluGlass has expanded its customer-funded GaN laser programs with a A$1.4 million Uviquity contract and a new A$286,000 photonics collaboration. But its A$8 million facility is fully drawn, carries 16.5% interest and leaves reported funding coverage at 2.8 quarters.

Zip delivered strong first-quarter growth, with total transaction volume up 18% to A$4.6 billion, but a US fraud event cost A$10.1 million and pushed group net bad debts higher. The company nevertheless reaffirmed its A$340 million FY27 cash EBTDA target, with September momentum offering an early test of whether the disruption was temporary.

Newmont Corporation (ASX:NEM) delivered record third-quarter adjusted net income of US$2.3 billion and US$1.9 billion in free cash flow, despite lower gold output and higher unit costs. The gold major also moved Red Chris closer to a potential US$4.2 billion to US$4.8 billion development decision in early 2027.

Lovisa delivered another year of strong reported growth, with revenue rising 17.6% to A$938.8 million as its store network passed 1,100 locations. But comparable store sales grew just 2.0%, leaving management’s expansion engine carrying more of the load while executive incentive hurdles went unmet.

Temple & Webster is holding to its FY27 EBITDA target of $33 million to $40 million even as revenue fell 8% in the first months of the year. The online retailer says reduced discounting is depressing sales but improving contribution margins, while AI, private-label products and brand investment move from testing into rollout.

Peet delivered record FY26 earnings as its proposed sale to Ingenia moves through the approval process. Profit rose 77% to $103.4 million, while contracts on hand climbed to $850.7 million and the fully franked dividend increased to 13 cents per share.

Bhagwan Marine reported $81.3 million in Q1 FY27 revenue, up 32% on the prior corresponding period, as subsea services and Riverside Industrial Sands led a stronger start to the year. Recurring revenue also increased to 64%, while new subsea awards and a Riverside Guardian contract added to the growth pipeline.

Black Cat Syndicate maintained its FY27 production and cost guidance despite a capital-heavy quarter that pushed cash and liquid investments down by A$27.7 million. Paulsens remained steady, while Kal East’s ramp-up and a new A$30 million cash improvement program now dominate the execution story.

Ora Banda Mining (ASX:OBM) kept its FY27 guidance intact despite weather disruption and an extended mill shutdown lifting quarterly AISC to A$4,214 an ounce. The company is spending heavily to build its next production phase, with the new 3.0 Mtpa plant on schedule and Waihi Underground starting ahead of plan.

Stavely Minerals has paired strong preliminary economics for its Thursday’s Gossan copper-gold-silver project with a much tighter near-term funding position. The company also reported higher-grade mineralisation at depth at the Freddy’s Find gold-silver prospect.

Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.

Mineral Resources has maintained FY27 guidance after a record quarter for mining services and lithium sales, while Onslow Iron delivered its strongest export month yet. The gains came with a sharp fall in lithium prices, elevated Mt Marion costs and a leadership change in the lithium division.

Talisman Mining has expanded the shallow gold footprint at its Sheepyard Prospect in New South Wales and is preparing RC drilling to test an untested anomaly at depth. The company has also raised about A$4 million, although part of the funding and director participation still require shareholder approval.

IKE has lowered its previously indicated FY27 subscription revenue growth expectation of about 35%, citing contract timing rather than weaker demand or churn. The NZX and ASX-listed software company still expects its subscription exit run rate to grow by more than 30% by March 2027, while three new products remain on track for launch.